Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:23:06.544Z.
Calculation as of: 2026-10-06T18:23:06.544Z.
Quote observation: 2026-10-06T18:19:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1639651ea08d8a43111aa8341d4d68762a5dc33ecadd1da8a92c037613eb041e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$49.47M
Price/OCF Ratio
N/A
TTM Avg
73.59
3Y Avg
628.92
5Y Avg
487.62
Market Cap
$44.75M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$44.54M
Price/OCF Ratio
8.53
TTM Avg
102.83
3Y Avg
129.05
5Y Avg
129.05
Market Cap
$44.40M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$49.90M
Price/OCF Ratio
N/A
TTM Avg
13.21
3Y Avg
14.20
5Y Avg
14.20
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Instil Bio, Inc. (TIL) | $47.41M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $48.15M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | N/A | 73.59 | 628.92 | 487.62 |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.75M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $48.77M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $44.54M | 8.53 | 102.83 | 129.05 | 129.05 |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $44.40M | N/A | N/A | N/A | N/A |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $49.90M | N/A | 13.21 | 14.20 | 14.20 |
| CVRx, Inc. (CVRX)vs › | $44.18M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
